Cost-Effectiveness of Breast Cancer Screening in Women on Dialysis

American Journal of Kidney Diseases

Volumn 52, Issue 5, 2008, Pages 916-929

  Wong, Germaine ^a,b   Howard, Kirsten ^b   Chapman, Jeremy R ^c   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

Breast neoplasm; cost effectiveness; mass screening

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEMODIALYSIS PATIENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PREVALENCE; PROBABILITY; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MAMMOGRAPHY; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 54149108977     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.06.015     Document Type: Article

References (63)

1. Gotzsche P.C., and Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 4 (2006) CD001877
2. Andersson I., Janzon L., and Sigfusson B.F. Mammographic breast cancer screening-A randomized trial in Malmo, Sweden. Maturitas 7 (1985) 21-29
3. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer 39 suppl 82 (1977) 2323-2964
4. Tabar L., Fagerberg G., Duffy S.W., Day N.E., Gad A., and Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 30 (1992) 187-210
5. Shen Y., and Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examinations. J Clin Oncol 19 (2001) 3490-3499
6. Gyrd-Hansen D., Holund B., and Andersen P. A cost-effectiveness analysis of cervical cancer screening: Health policy implications. Health Policy 34 (1995) 35-51
7. Hall J., Gerard K., Salkeld G., and Richardson J. A cost utility analysis of mammography screening in Australia. Soc Sci Med 34 (1992) 993-1004
8. Leivo T., Sintonen H., Tuominen R., Hakama M., Pukkala E., and Heinonen O.P. The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. Cancer 86 (1999) 638-646
9. Lindfors K.K., and Rosenquist C.J. The cost-effectiveness of mammographic screening strategies. JAMA 274 (1995) 881-884
10. Vajdic C.M., McDonald S.P., McCredie M.R., et al. Cancer incidence before and after kidney transplantation. JAMA 296 (2006) 2823-2831
11. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: Prevention and treatment. Nephrol Dial Transplant 17 Suppl 4 (2002) 32 34-36
12. Kasiske B.L., Vazquez M.A., Harmon W.E., et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11 suppl 86 (2000) S1-S86
13. Winkelmayer W.C., Owen W., Glynn R.J., Levin R., and Avorn J. Preventive health care measures before and after start of renal replacement therapy. J Gen Intern Med 17 (2002) 588-595
14. Chertow G.M., Paltiel A.D., Owen Jr. W.F., and Lazarus J.M. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 156 (1996) 1345-1350
15. LeBrun C.J., Diehl L.F., Abbott K.C., Welch P.G., and Yuan C.M. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis 35 (2000) 237-243
16. Briggs A., and Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 4 (1998) 397-409
17. Walter L.C., Lindquist K., O'Hare A.M., and Johansen K.L. Targeting screening mammography according to life expectancy among women undergoing dialysis. Arch Intern Med 166 (2006) 1203-1208
18. Tabar L., Duffy S.W., Yen M.F., et al. All-cause mortality among breast cancer patients in a screening trial: Support for breast cancer mortality as an end point. J Med Screen 9 (2002) 159-162
19. The Australian Institute of Health and Welfare and the Australian Government Department of Health and Ageing for the BreastScreen Australia Program. BreastScreen Australia Monitoring Report 2001-2002 (2003), Australian Institute of Health and Welfare, Canberra, Australia
20. Brewer N.T., Salz T., and Lillie S.E. Systematic review: The long-term effects of false-positive mammograms. Ann Intern Med 146 (2007) 502-510
21. Silverstein M.J., Recht A., and Lagios M. Overview of Conservation Surgery and Radiation Therapy: Ductal Carcinoma In Situ. (ed 2) (2002), Lippincott Williams & Wilkins, Philadelphia, PA 287-302
22. Fisher B., Land S., Mamounas E., Dignam J., Fisher E.R., and Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28 (2001) 400-418
23. Australia Institute of Health and Welfare, National Breast Cancer Centre. Breast Cancer in Australia: An Overview, 2006 (2006), Australian Institute of Health and Welfare, Canberra, Australia
24. Austalian Government Australia Institute of Health and Welfare. AR-DRG Data Cubes From 2004-2005 (2005), Australian Government Department of Health and Ageing, Canberra, Australia
25. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book (2006), Australian Government Department of Health and Ageing, Canberra, Australia
26. Webster A.C., Craig J.C., Simpson J.M., Jones M.P., and Chapman J.R. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 7 (2007) 2140-2151
27. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., and Weissert W.G. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 20 (2000) 332-342
28. George B., Harris A., and Mitchell A. Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19 (2001) 1103-1109
29. Harris A., Hill S.R., Chin J., Li J.J., and Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994-2004. Med Decis Making (2008) Mar 31 [Epub ahead of print]
30. Quinn R.R., Naimark D.M., Oliver M.J., and Bayoumi A.M. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation?. A cost-utility analysis [see comment]. Am J Kidney Dis 50 (2007) 421-432
31. Castellanos M., Varma S., Ahern K., et al. Increased breast calcifications in women with ESRD on dialysis: Implications for breast cancer screening. Am J Kidney Dis 48 (2006) 301-306
32. Miller A.B., To T., Baines C.J., and Wall C. The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137 Pt 1 (2002) 305-312
33. Basnakian A.G., Apostolov E.O., Yin X., Napirei M., Mannherz H.G., and Shah S.V. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol 16 (2005) 697-702
34. Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., and Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25 (2007) 3808-3815
35. Chapman J.R., and Webster A.W. Cancer Report, chap 10. The 25th Annual ANZDATA Registry Report 2002 (2003), Australian and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia 83-90
36. Evans A.J., Cohen M.E., and Cohen G.F. Patterns of breast calcification in patients on renal dialysis. Clin Radiol 45 (1992) 343-344
37. Brett J., Bankhead C., Henderson B., Watson E., and Austoker J. The psychological impact of mammographic screening. A systematic review. Psychooncology 14 (2005) 917-938
38. Brodersen J., Thorsen H., and Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. J Med Screen 11 (2004) 39-44
39. Bloembergen W.E., Port F.K., Mauger E.A., and Wolfe R.A. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 6 (1995) 184-191
40. Berrington de G.A., and Reeves G. Mammographic screening before age 50 years in the UK: Comparison of the radiation risks with the mortality benefits. Br J Cancer 93 (2005) 590-596
41. Glasziou P., and Irwig L. The quality and interpretation of mammographic screening trials for women ages 40-49. J Natl Cancer Inst 22 (1997) 73-77
42. Wong G., Howard K., Craig J.C., MacDonald S., and Chapman J.R. Cancer Report, chap 10. The 29th Annual ANZDATA Registry Report 2006 (2006), Australian and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia 137-142
43. Barratt A.L., Les I.M., Glasziou P.P., Salkeld G.P., and Houssami N. Benefits, harms and costs of screening mammography in women 70 years and over: A systematic review. Med J Aust 176 (2002) 266-271
44. Gorodetskaya I., Zenios S., McCulloch C.E., et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 68 (2005) 2801-2808
45. Gudex C.M. Health-related quality of life in endstage renal failure. Qual Life Res 4 (1995) 359-366
46. Kiberd B.A., Keough-Ryan T., and Clase C.M. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant 3 (2003) 619-625
47. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Special Data Request (2005) (2005), Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, South Australia
48. Mushlin A.I., Kouides R.W., and Shapiro D.E. Estimating the accuracy of screening mammography: A meta-analysis. Am J Prev Med 14 (1998) 143-153
49. Betsill Jr. W.L., Rosen P.P., Lieberman P.H., and Robbins G.F. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239 (1978) 1863-1867
50. Rosen P.P., Braun Jr. D.W., and Kinne D.E. The clinical significance of pre-invasive breast carcinoma. Cancer 46 suppl 25 (1980) 919-925
51. Page D.L., Dupont W.D., Rogers L.W., and Landenberger M. Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 49 (1982) 751-758
52. Sanders M.E., Schuyler P.A., Dupont W.D., and Page D.L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103 (2005) 2481-2484
53. Andersson I., and Sigfusson B.F. Screening for breast cancer in Malmo: A randomized trial. Recent Res Cancer Res 105 (1987) 62-66
54. Frisell J., Glas U., Hellstrom L., and Somell A. Randomized mammographic screening for breast cancer in Stockholm. Design, first round results and comparisons. Breast Cancer Res Treat 8 (1986) 45-54
55. Tabar L., Gad A., Holmberg L., and Ljungquist U. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagn Imaging Clin Med 54 (1985) 158-164
56. Pejavar S., Wilson L.D., and Haffty B.G. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys 66 (2006) 1320-1327
57. Faneyte I.F., Peterse J.L., Van Tinteren H., et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 10 (2004) 4457-4463
58. Barratt A., Howard K., Irwig L., Salkeld G., and Houssami N. Model of outcomes of screening mammography: Information to support informed choices. BMJ 330 (2005) 351-356
59. Rhodes A., Jasani B., Balaton A.J., Barnes D.M., and Miller K.D. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53 (2000) 688-696
60. Bland K.I., Menck H.R., Scott-Conner C.E., Morrow M., Winchester D.J., and Winchester D.P. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 83 (1998) 1262-1273
61. Cancer Institute NSW. Standard cancer treatment. https://www.treatment.cancerinstitute.org.au/cancerinstitute Accessed September 29, 2007
62. Fassbender K., Fainsinger R., Brenneis C., Brown P., Braun T., and Jacobs P. Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000. Palliat Med 19 (2005) 513-520
63. Guest J.F., Ruiz F.J., Greener M.J., and Trotman I.F. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care 15 (2006) 65-73